DDInter119 DDInter1615
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and late-phase CINV during the first 120 hours post-chemotherapy.
Rolapitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Rolapitant may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Rolapitant may lead to a major life threatening interaction when taken with Enzalutamide
Rolapitant may lead to a major life threatening interaction when taken with Betrixaban